Investment
Features
FeesSafety
Academy
More
Pluang+

Mama's Creations posts strong Q2 growth, but stock value nears fair price at $15.8

Company Fundamentals
08 Sep 2026
Seeking Alpha
View Source
Neutral
Mama's Creations posts strong Q2 growth, but stock value nears fair price at $15.8

Mama's Creations reported solid fiscal Q2 results driven by the acquisition of Bay Shore and organic growth, boosting both revenue and profit. Continued distribution gains support the company's expansion strategy. However, the estimated fair value of the stock is $15.8, indicating limited upside potential for investors. This suggests the stock is fairly valued at current levels, with modest expectations for future price increases.

More News

Intel shares jump on High-NA EUV tech progress and $120 price target upgrade

Intel shares jump on High-NA EUV tech progress and $120 price target upgrade

Intel's stock surged after Northland Securities upgraded it from "Market Perform" to "Outperform" with a $120 price target, following Intel Foundry's progress in High Numerical Aperture Extreme Ultraviolet (High-NA EUV) lithography. Intel has process...

Market News
Bullish
2 hours ago
ABM Industries beats Q3 EPS estimates with $1.04, posts record $2.3B revenue and strong cash flow.

ABM Industries beats Q3 EPS estimates with $1.04, posts record $2.3B revenue and strong cash flow.

ABM Industries reported strong Q3 2026 results, surpassing analyst EPS estimates with $1.04 per share versus the expected $1.01. The company achieved record revenue of $2.3 billion, a 4.2% increase driven by organic and acquisition growth. Adjusted n...

Company Fundamentals
Bullish
2 hours ago
GameStop Q2 earnings show revenue drop but focus on strategic fund use and financial health.

GameStop Q2 earnings show revenue drop but focus on strategic fund use and financial health.

GameStop is set to report its Q2 2026 earnings with analysts expecting an EPS of $0.27 and revenues around $756.85 million, down from $972.20 million the previous year. The company’s own sales forecast of $780-$800 million confirms a significant reve...

Company Fundamentals
Neutral
2 hours ago
Opus Genetics gets Buy rating ahead of key gene therapy data release on Sept 9, 2026.

Opus Genetics gets Buy rating ahead of key gene therapy data release on Sept 9, 2026.

Opus Genetics, a clinical-stage biotech focused on inherited retinal diseases, received a Buy rating and $8 price target from analyst Matthew Caufield in August 2026. The company plans to release topline Phase 1/2 data for its gene therapy OPGx-BEST1...

Analyst Insights
Bullish
3 hours ago
GE to acquire CPP for $11.75B, boosting aerospace casting capacity and earnings potential

GE to acquire CPP for $11.75B, boosting aerospace casting capacity and earnings potential

General Electric (GE) announced it will acquire Consolidated Precision Products (CPP) for $11.75 billion to enhance its aerospace casting production. This strategic move aims to strengthen GE's manufacturing capabilities and accelerate engine technol...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App